Absci Corp. ( (ABSI) ) has released its Q3 earnings. Here is a breakdown of the information Absci Corp. presented to its investors. Absci ...

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Absci (ABSI) now expects a gross use of cash, cash equivalents, and short-term investments of approximately $75 million, below the previous ...

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody ...

Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago. These figures ...

VANCOUVER, Wash. and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience ...

Absci Corporation is a U.S.-based company that uses generative AI and scalable wet lab technologies to accelerate biologic drug creation by optimizing multiple drug characteristics simultaneously ...

and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended ...

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report ...